Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Evelo Biosciences Inc (EVLO)

Evelo Biosciences Inc (EVLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,858
  • Shares Outstanding, K 32,086
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,950 K
  • 60-Month Beta -0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.67
  • Number of Estimates 1
  • High Estimate -0.67
  • Low Estimate -0.67
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -36.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.79 +17.15%
on 12/09/19
6.58 -32.52%
on 11/13/19
-2.09 (-32.01%)
since 11/12/19
3-Month
3.79 +17.15%
on 12/09/19
9.27 -52.08%
on 09/19/19
-3.45 (-43.73%)
since 09/12/19
52-Week
3.79 +17.15%
on 12/09/19
15.89 -72.06%
on 01/07/19
-5.50 (-55.33%)
since 12/12/18

Most Recent Stories

More News
Evelo Biosciences Appoints Juan Andres to Board of Directors

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical...

LLY : 121.44 (+0.55%)
EVLO : 4.50 (+2.51%)
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 3.50 (-1.13%)
DNLI : 18.54 (+2.43%)
EVLO : 4.50 (+2.51%)
KLDO : 5.69 (+10.49%)
MRNA : 18.62 (-0.16%)
RUBY : 12.99 (+1.17%)
MCRB : 4.16 (+1.71%)
SYRS : 4.61 (-0.43%)
Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present...

EVLO : 4.50 (+2.51%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 92.88 (-0.17%)
AXLA : 3.50 (-1.13%)
DNLI : 18.54 (+2.43%)
EVLO : 4.50 (+2.51%)
KLDO : 5.69 (+10.49%)
MRNA : 18.62 (-0.16%)
RUBY : 12.99 (+1.17%)
MCRB : 4.16 (+1.71%)
SYRS : 4.61 (-0.43%)
Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology...

EVLO : 4.50 (+2.51%)
Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial

--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo--

EVLO : 4.50 (+2.51%)
Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results

--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo--

EVLO : 4.50 (+2.51%)
Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, November 5th

Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call...

EVLO : 4.50 (+2.51%)
Evelo Biosciences to Present at the 2019 Cantor Global Healthcare Conference

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that management will present a corporate overview...

EVLO : 4.50 (+2.51%)
Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium...

EVLO : 4.50 (+2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EVLO with:

Business Summary

Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts,...

See More

Key Turning Points

2nd Resistance Point 4.70
1st Resistance Point 4.54
Last Price 4.50
1st Support Level 4.19
2nd Support Level 4.00

See More

52-Week High 15.89
Fibonacci 61.8% 11.27
Fibonacci 50% 9.84
Fibonacci 38.2% 8.41
Last Price 4.50
52-Week Low 3.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar